Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.
Melisa M ShahBrendan JoyceIan D PlumbSam SahakianLeora R FeldsteinEric BarkleyMason PaccioneJoseph DeckertDanessa SandmannMelissa Briggs HagenJacqueline L GerhartPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19-.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment.